Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.

Merck and Moderna reported positive topline Phase 3 results from INTerpath-001 for intismeran autogene (individualized neoantigen therapy) combined with Keytruda in resected melanoma. While the article does not specify efficacy magnitude or endpoints, a Phase 3 readout is a meaningful catalyst that could materially improve the outlook for both programs. Expect above-market sensitivity in MRK and MRNA tied to the trial’s next data release.